Resources & Insights

Driving factors that lead to cancer spread in the brain, magnetic bacteria in oncology research, and immune boosting therapy — we’ve rounded up interesting oncology news for December 2020.

PharPoint’s passion to improve global health isn’t just limited to the work we do for clients. This year, we were overjoyed to have collected over 500 lbs of food donations for our communities in Wilmington, NC and Durham, NC.

How do our experts produce quality statistical analyses? Proper planning, processes & review are critical.

As we round out November 2020, we’re reading about a successful COVID-detecting AI model, a promising relationship between the MMR vaccine & COVID-19, and a new study behind the causes of fatal influenza.

In this weeks oncology round-up, we’ve gathered information on the role of long non-coding RNAs in the development of pancreatic cancer, insight into a gene signature in localized prostate cancer, and new applications of cells in cancer therapies.

In addition to the huge news of an FDA approval of the first treatment for COVID-19 (Gilead Science’s antiviral IV drug remdesivir), we’re looking at the FDA approval of the first treatment for Ebola, as well as a novel microneedle-based skin patch.

What’s new in oncology for October 2020? We’ve rounded up information on potential cancer-reducing drugs, liquid biopsy to detect brain tumors, and new immune-like characteristics of cells.

When you’re working with a big name, “big-box” CRO, there are a few pitfalls to watch out for as a small to mid-sized biotech or pharmaceutical company.

In addition to continued progress and information regarding the ongoing COVID-19 pandemic, October brings forth information on predicting this seasons influenza strain, the body’s response to viral infection, and a potential rotavirus cure.

Explore PharPoint’s values in action: what makes the team at PharPoint different?